These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 32741080)
1. Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer. Wood ME; McKinnon W; Garber J Breast J; 2020 Aug; 26(8):1528-1534. PubMed ID: 32741080 [TBL] [Abstract][Full Text] [Related]
2. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer. Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
5. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005 [TBL] [Abstract][Full Text] [Related]
6. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know. Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561 [TBL] [Abstract][Full Text] [Related]
7. Screening for familial cancer risk: Focus on breast cancer. Rousset-Jablonski C; Gompel A Maturitas; 2017 Nov; 105():69-77. PubMed ID: 28818315 [TBL] [Abstract][Full Text] [Related]
8. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? Angeli D; Salvi S; Tedaldi G Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046255 [TBL] [Abstract][Full Text] [Related]
9. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496 [TBL] [Abstract][Full Text] [Related]
10. Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants. Hudson L; Gower N; Lenarcic S; Trufan SJ; White RL Ann Surg Oncol; 2020 Jul; 27(7):2248-2254. PubMed ID: 31974710 [TBL] [Abstract][Full Text] [Related]
11. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients. Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725 [TBL] [Abstract][Full Text] [Related]
12. Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA. Piombino C; Cortesi L; Lambertini M; Punie K; Grandi G; Toss A J Oncol; 2020; 2020():6384190. PubMed ID: 32733558 [TBL] [Abstract][Full Text] [Related]
13. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition]. Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C; Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633 [TBL] [Abstract][Full Text] [Related]
14. Hereditary genes and SNPs associated with breast cancer. Mahdi KM; Nassiri MR; Nasiri K Asian Pac J Cancer Prev; 2013; 14(6):3403-9. PubMed ID: 23886119 [TBL] [Abstract][Full Text] [Related]
15. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management. Kleibl Z; Kristensen VN Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer and ovarian cancer genetics. Edlich RF; Winters KL; Lin KY J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901 [TBL] [Abstract][Full Text] [Related]
17. Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing. Rosenthal ET; Evans B; Kidd J; Brown K; Gorringe H; van Orman M; Manley S J Am Coll Radiol; 2017 Apr; 14(4):561-568. PubMed ID: 28011157 [TBL] [Abstract][Full Text] [Related]
19. Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. Wang X; Teer JK; Tousignant RN; Levin AM; Boulware D; Chitale DA; Shaw BM; Chen Z; Zhang Y; Blakeley JO; Acosta MT; Messiaen LM; Korf BR; Tainsky MA Genes Chromosomes Cancer; 2018 Jan; 57(1):19-27. PubMed ID: 28891274 [TBL] [Abstract][Full Text] [Related]